New hope for retinitis pigmentosa patients outside clinical trial
NCT ID NCT06574997
First seen Apr 15, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This program offers up to 75 adults with retinitis pigmentosa access to an experimental treatment called OCU400. It is for people who cannot join the main Phase 3 study and have no other FDA-approved options. The goal is to provide treatment while gathering more safety and effectiveness data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Advanced Research
Deerfield Beach, Florida, 33064, United States
-
Associated Retina Consultants
Phoenix, Arizona, 85020, United States
-
Erie Retina Research
Erie, Pennsylvania, 16507, United States
-
Gundersen Health
La Crosse, Wisconsin, 54601, United States
Conditions
Explore the condition pages connected to this study.